Avelox Lawsuits Over Nerve Damage Set for Trials to Begin November 2018
The U.S. District Judge presiding over all federal lawsuits over nerve damage caused by a class of antibiotics known as fluoroquinolone, which include Levaquin, Avelox, Cipro and others, has announced that the first bellwether trial will go before a jury in November 2018.
There are currently more than 750 Avelox lawsuits, Levaquin lawsuits and Cipro lawsuits centralized before U.S. District Judge John R. Tunheim in the District of Minnesota, as part of a federal MDL or multidistrict litigation.
Each of the complaints raise similar allegations that the manufacturers of the fluoroquinolone-based antibiotics failed to adequately warn consumers and the medical community about the risk of developing a painful and debilitating condition, known as peripheral neuropathy, which may continue long after the medications are no longer used.
As part of the coordinated pretrial proceedings in the MDL, small groups of peripheral neuropathy lawsuits have been prepared for early trial dates, known as “bellwether” cases, since they are designed to help the parties gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.
In a pretrial order (PDF) issued on October 12, Judge Tunheim provided an updated schedule for case-specific discovery and bellwether trials, which will begin with an Avelox lawsuit going before a jury in November 2018.
The parties have been directed to complete all non-expert fact discovery deadline for cases involving Avelox and Cipro by January 26, 2018, with a deadline for expert discovery set for May 4.
The parties will submit briefings in early February 2018, identifying the specific cases that each side believes should be the first to go to trial.
Judge Tunheim indicates that the first Avelox bellwether trial will begin in November 2018, followed by a second Avelox case beginning in January 2019, a Cipro trial in March 2019, and two more Avelox trials in June and August 2019.
Fluoroquinolone Peripheral Neuropathy Litigation
The antibiotic litigation has emerged since the FDA required makers of all fluoroquinolones to update the warning labels in August 2013, adding information about the risk that nerve damage may be permanent.
While prior warnings provided with drugs like Levaquin, Avelox and Cipro indicated that some users experienced temporary nerve damage in rare cases, plaintiffs allege that the drug makers should have provided much stronger warnings and disclosed the risk of long-lasting peripheral neuropathy, which may last for months or even years.
Peripheral neuropathy involves damage to the nerves that may impair sensation, movement and other aspects of health. This may leave users with persistent pain, burning, tingling, numbness, weakness and sensitivity to light touches, temperature and motion in the arms and legs, as well as other problems that cause a major disruption to daily activities.
Plaintiffs allege that the makers of Levaquin, Avelox and Cipro should have provided these warnings years ago, noting that the first indication of a possible link between long-term peripheral neuropathy and fluoroquinolone antibiotics came in a study published in 2001. If adequate warnings had been provided about the risk of permanent neuropathy problems, plaintiffs indicate that they may have avoided painful and debilitating injuries.
Given the risk of nerve damage and other injuries associated with the antibiotics, the FDA issued a new drug safety communication in May 2016, urging doctors not to prescribe fluoroquinolones for many common infections that are uncomplicated and have other available treatment options, indicating that the risks associated with the antibiotics outweigh the benefits.
The federal regulatory agency considered available information on the risk of peripheral neuropathy, tendon ruptures, retinal detachments and other health concerns linked to the drugs at that time.
More recently, research has also suggested that the same collagen degradation issues that cause the drugs to increase the risk of tendon ruptures and retinal detachment may impact the aorta.
As a result, a growing number of aortic aneurysm lawsuits and aortic dissection lawsuits are also being pursued against the drug makers, alleging that the painful and potentially life-threatening complication may have been avoided if proper warnings had been provided to users of the antibiotics.
If no settlement agreement is reached during the pretrial proceedings, all cases would be remanded back to their originating district for individual trial.